The identification of mutations affecting members of the MAP-kinase pathway in histiocytosis lesions is important both to confirm the diagnosis and to identify possible therapeutic targets (e.g. BRAF-V600E mutation, MEK inhibition). This evidence concerns the gene BRAF and Histiocytosis.